Comparative Pharmacology
Head-to-head clinical analysis: KANTREX versus NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANTREX versus NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN.
KANTREX vs NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a polypeptide antibiotic that disrupts bacterial cell membrane permeability by interacting with phospholipids. Gramicidin is a polypeptide antibiotic that increases cell membrane permeability by forming ion channels, leading to bacterial cell death.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
Instill 2 drops (or appropriate amount) into affected eye(s) every 2-4 hours for 7-10 days. Frequency may be increased to every 1-2 hours in severe infections. Ophthalmic suspension, not for injection.
None Documented
None Documented
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Neomycin: 2-3 hours (normal renal function); polymyxin B: 6-8 hours; gramicidin: ~10 hours (estimated from topical absorption). Prolonged in renal impairment, especially for polymyxin B.
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Renal: ~95% for neomycin (unchanged), minimal for polymyxin B (1-10% unchanged) and gramicidin (<1%). Fecal: 50-60% for polymyxin B (biliary), ~1% for neomycin.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic